Evidence map›Paper›PMID 26657044›Full record

Trial reportArchives of medical research2015

Exploring Glycan Markers for Immunotyping and Precision-targeting of Breast Circulating Tumor Cells.

Denong Wang, Xiaohe Liu, Ben Hsieh, Richard Bruce, George Somlo, Jiaoti Huang, Lidia Sambucetti

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Archives of medical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Liquid Biopsy in the OMICS Era of Tumor Medicine.Open access journal of biomedical engineering and its applications · 2018
    Article
  8. Unraveling Sugar Chain Signatures of the "Seeds" of Tumor Metastasis.Journal of proteomics & bioinformatics · 2017
    Article
  9. Glycan Markers as Potential Immunological Targets in Circulating Tumor Cells.Advances in experimental medicine and biology · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Denong WangTumor Glycomics Laboratory, Menlo Park, California, USA; SRI International Biosciences Division, Menlo Park, California, USA. Electronic address: denong.wang@sri.com.
Xiaohe LiuSRI International Biosciences Division, Menlo Park, California, USA.
Ben HsiehPalo Alto Research Center, Palo Alto, California, USA.
Richard BrucePalo Alto Research Center, Palo Alto, California, USA.
George SomloDepartments of Medical Oncology and Therapeutics Research, City of Hope Cancer Center, Duarte, California, USA.
Jiaoti HuangDepartment of Pathology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Lidia SambucettiSRI International Biosciences Division, Menlo Park, California, USA.

Funding

High-speed reliable detection of cancer cells in bloodR01CA111359 · NCI · PALO ALTO RESEARCH CENTER · PI BRUCE, RICHARD H. · 2006 to 2010
$4.9M
Immunogenic sugar moieties of prostate cancersU01CA128416 · NCI · STANFORD UNIVERSITY · PI WANG, DENONG · 2007 to 2011
$2.3M
A T-independent pathway of B cell responses to oligomannosyl antigens of HIV-1R56AI108388 · NIAID · SRI INTERNATIONAL · PI WANG, DENONG · 2013 to 2013
$751k
NCI NIH HHS CA111359NCI NIH HHS R01 CA111359NCI NIH HHS U01 CA128416NCI NIH HHS U01CA128416NIAID NIH HHS R56 AI108388NIAID NIH HHS R56AI108388
6 · The paper itself

Abstract

BACKGROUND AND

aimsRecognition of abnormal glycosylation in virtually every cancer type has raised great interest in exploration of the tumor glycome for biomarker discovery. Identifying glycan markers of circulating tumor cells (CTCs) represents a new development in tumor biomarker discovery. The aim of this study was to establish an experimental approach to enable rapid screening of CTCs for glycan marker identification and characterization.

methodsWe applied carbohydrate microarrays and a high-speed fiber-optic array scanning technology (FAST scan) to explore potential glycan markers of breast CTCs (bCTCs) and targeting antibodies. An anti-tumor monoclonal antibody, HAE3-C1 (C1), was identified as a key immunological probe in this study.

resultsIn our carbohydrate microarray analysis, C1 was found to be highly specific for an O-glycan cryptic epitope, gp(C1). Using FAST-scan technology, we established a procedure to quantify expression levels of gp(C1) in tumor cells. In blood samples from five stage IV metastatic breast cancer patients, the gp(C1) positive CTCs were detected in all subjects; ∼40% of bCTCs were strongly gp(C1) positive. Interestingly, CTCs from a triple-negative breast cancer patient with multiple sites of metastasis were predominantly gp(C1) positive (92.5%, 37/40 CTCs).

conclusionsTogether we present here a practical approach to examine rare cell expression of glycan markers. Using this approach, we identified an O-core glyco-determinant gp(C1) as a potential immunological target of bCTCs. Given its bCTC-expression profile, this target warrants an extended investigation in a larger cohort of breast cancer patients.

Indexed as

AdultAntibodies, MonoclonalBiomarkers, TumorBreast NeoplasmsCell Line, TumorFemaleGlycosylationHumansMiddle AgedNeoplastic Cells, CirculatingPilot ProjectsPolysaccharidesAntibodies, MonoclonalBiomarkers, TumorPolysaccharidesCarbohydrate microarraysCirculating tumor cellsMetastatic breast cancerO-glycan cryptic antigensTumor immunotyping

Identifiers

PMID26657044
PMCPMC4729604

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.